Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Enocsson, HelenaWirestam, Lina
Dahle, Charlotte
Padyukov, Leonid
Jönsen, Andreas
Urowitz, Murray B
Gladman, Dafna D
Romero-Diaz, Juanita
Bae, Sang-Cheol
Fortin, Paul R
Sanchez-Guerrero, Jorge
Clarke, Ann E
Bernatsky, Sasha
Gordon, Caroline
Hanly, John G
Wallace, Daniel J
Isenberg, David A
Rahman, Anisur
Merrill, Joan T
Ginzler, Ellen
Alarcón, Graciela S
Chatham, W Winn
Petri, Michelle
Khamashta, Munther
Aranow, Cynthia
Mackay, Meggan
Dooley, Mary Anne
Manzi, Susan
Ramsey-Goldman, Rosalind
Nived, Ola
Steinsson, Kristjan
Zoma, Asad A
Ruiz-Irastorza, Guillermo
Lim, S Sam
Kalunian, Kenneth C
Inanc, Murat
van Vollenhoven, Ronald F
Ramos-Casals, Manuel
Kamen, Diane L
Jacobsen, Søren
Peschken, Christine A
Askanase, Anca
Stoll, Thomas
Bruce, Ian N
Wetterö, Jonas
Sjöwall, Christopher
Issue Date
2019-10-17
Metadata
Show full item recordCitation
Enocsson H, Wirestam L, Dahle C, et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020;106:102340. doi:10.1016/j.jaut.2019.102340Abstract
Objective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE. Methods: Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI). Results: The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03-1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007). Conclusion: Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.Description
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadRights
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.ae974a485f413a2113503eed53cd6c53
10.1016/j.jaut.2019.102340
Scopus Count
Collections